On April 21, 2020 Omniscience reported that New Horizon Health of Hangzhou completed a $20 million Series D financing to support its early-stage cancer screening products (Press release, Omniscience, APR 21, 2020, View Source [SID1234556486]). Founded in 2013, New Horizon has launched at-home cancer screening products for colorectal cancer, cervical cancer, gastric cancer and lung cancer. The company claims to have served more than three million customers. New Horizon plans to use the funds to develop new products, make a large-scale investment in clinical research and upgrade its service system. The round was led by Omniscience, a private equity fund.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!